Dr. Osborne on Pertuzumab in HER2+ Breast Cancer

C. Kent Osborne, MD: Breast Cancer Treatment - A Year In ReviewПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast CancerПодробнее

Dr. Kolberg on Cost-Effectiveness of Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Osborne on Evaluating HER2-Positivity in Breast CancerПодробнее

Dr. Osborne Discusses the Future of Treatment in HER2+ Breast CancerПодробнее

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast CancerПодробнее

Dr. Osborne on the PRIME 2 TrialПодробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast CancerПодробнее

Dr. Pegram on Pertuzumab and Trastuzumab in Breast CancerПодробнее

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Geyer Discusses Pertuzumab in HER2+ Breast CancerПодробнее

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast CancerПодробнее

Dr. Mittendorf on the Impact of Pertuzumab in HER2+ Breast CancerПодробнее

PRECIOUS: pertuzumab retreatment in patients with HER+ breast cancerПодробнее

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast CancerПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast CancerПодробнее